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Background: Inter- and intra-subject variability of oral busulfan (Bu)
absorption from the gastrointestinal tract may contribute to busulfan
overexposure, resulting in unfavorable post-transplant adverse events
i.e. veno-occlusive disease. Intravenous (IV) Bu helps to circumvent
this problem by decreasing variability in drug exposure. However,
inter-subject variability of Bu exposure still exists due to differences in
Bu clearance. This multi-institutional, prospective Phase 2 study exam-
ined if pharmacokinetic (PK) modeling based upon a small test dose
prior to the preparative regimen can provide optimized dosing of IVBu.
Methods: Patients with chemo-sensitive relapsed or primary-refrac-
tory lymphoma undergoing a first autologous hematopoietic stem
cell transplantation received a test dose of IV Bu (0.8 mg/kg) given as
a 2 hour continuous infusion on a day between Days -14 and -11. Bu
exposure was determined as area under the concentration-time curve
(AUC) using six whole blood samples obtained at defined intervals after
the end of the infusion. Based on test PK, the remaining Bu dose was
calculated to achieve a total AUC of 20,000 mM$min. One-fourth of
this dose was given as a 3 hour infusion on Day -8, during which a sec-
ond PK analysis was done.The same daily Bu dose was administered on
Days -7, -6, and -5 unless Day -8 PK results showed total AUC outside
the target6 20%. Etoposide 1400mg/m2 was administered onDay -4,
followed by cyclophosphamide 2.5 g/m2/day on Days -3 and -2.
Results: A total of 145 subjects with non-Hodgkin’s (n 5 96) and
Hodgkin’s lymphoma (n 5 49) were enrolled from 32 centers in
the US and Canada. This analysis includes 137 subjects who had
both test PK and Day -8 PK. 52 (38%) patients required dose alter-
ation as a result of test PK. 47 (34.3%) patients required a dose in-
crease, whereas 5 (3.6 %) required a dose decrease. These 52
subjects would have been dosed outside the total target AUC range
during conditioning if test PKwas not performed. The test PK accu-
rately predicted the Day -8 PK. Based on Day -8 PK, only 5 (3.6%)
patients required dose adjustment on Days -6 and -5.
Table. Bu Exposure from Test PK and Day -8 PK
Patient Patient PatientS246Number
(% and 95% CI)Number
(% and 95% CI)Number
(% and 95% CI)AUC (mMmin) < 1000 1000-1500 > 1500
Test PK from
0.8 mg/kgn 5 47 (34.3%,
26.8-42.6)n 5 85 (62.0%,
53.7-69.7)n 5 5 (3.6%,
1.3-8.5)AUC (mMmin) < 16, 000 16, 000-24, 000 > 24, 000
Day -8 PK from
Individual dosesn 5 3 (2.18%,
0.7-6.2)n 5 132 (96.4%,
51.5-98.6)n 5 2
(1.45%, 0.4-5.2)Conclusion: A pretransplant test PK of IV Bu is feasible in a multi-
institutional setting, provides optimized dosing during the condition-
ing regimen and prevents the Bu overexposure or underexposure that
would have occurred in over a third of patients. Intra-patient changes
in Bu clearance between test dose and conditioning dose are minimal.
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Introduction: Busulfan (Bu) based conditioning regimens were devel-
oped for use in ASCT for HLwith the goal to reduce the risk of relapse
without increasing toxicity incomparison tomoreconventional regimens
such asBEAM.AtOhioState, Buwas combinedwith cyclophosphamide
(CY) andVP-16 (BUCYVP) and became the standard conditioning reg-
imen here for 15 years. In 2005, we switched to the BEAM regimen.
Methods: We retrospectively analyzed 188 patients with HL who
underwent ASCT between 1990 and 2010. Cumulative incidence
of relapse (CIR) was measured from transplant date until relapse,
treating deaths as competing risks using Gray’s method. Among pa-
tients with adequate follow-up, proportions of early deaths were
compared using Fisher’s exact test. In relapsed patients, survival
was measured from relapse date until death from any cause.
Results:Median age at transplant was 33 years with 60% of patients
male. Prior to ASCT, 64% received BUCYVP and 36% received
BEAM. Median follow-up among patients relapse-free and alive
was 109 and 16 months, respectively for BUCYVP and BEAM pa-
tients. Those receiving BUCYVPhad higher CIR compared to those
receiving BEAM, approaching statistical significance (p 5 0.06).
When controlling for response status at transplant (p 5 0.03) and
number of prior chemotherapy lines, conditioning regimen did not
predict risk of relapse (p5 0.11; HR5 1.5, 95% CI: 0.9-2.6). How-
ever, 5% and 8% of BUCYVP patients suffered from non-relapse
mortality at 6 and 12 months, respectively, compared to 0 of 67 and
0 of 48 BEAM patients (p 5 0.06 at 12 months). Of 79 relapsed pa-
tients, estimatedmedian survival was 16.5months andwas not differ-
ent between conditioning regimens (p 5 0.96).
Conclusion: Although treatment period differed and more BUCYVP
patients were refractory (39% versus 16%), our experience in HL does
not support that more stringent Bu-based conditioning offers advan-
tages comparedwith BEAMand in factmay be significantlymore toxic.
Table. Cumulative Incidence of Relapse Estimates in Presence
of Competing Risks
All Patients BUCYVP BEAM P crudeCIR N 5 188 N 5 120 N 5 68 (P adjusted)Median (months) Not Reached 50 Not Reached 0.06 (0.11)% relapsed (95% CI)at 12 months 26 (20-33) 29 (21-38) 20 (10-30)at 18 months 36 (29-43) 39 (31-48) 28 (15-40)at 24 months 39 (31-46) 43 (34-52) 28 (15-40)116
PHASE I/II STUDY OF VELCADE®-BEAM (V-BEAM) AND AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANTATION (ASCT) FOR RELAPSED
INDOLENT NON-HODGKIN’S LYMPHOMA (NHL), TRANSFORMED OR
MANTLE CELL LYMPHOMA (MCL)
William, B.M., Allen, M.S., Loberiza, F.R., Bociek, R.G., Bierman, P.J.,
Armitage, J.O.,Vose, J.M.University ofNebraskaMedical Center,Omaha,NE
A phase I/II trial was designed to evaluate the safety and activity of
adding bortezomib to standard BEAM (BCNU, etoposide,
